Trial Profile

A prospective, observational study providing real-world evidence of fremanezumab treatment outcomes in European clinical practice in patients with episodic migraine (EM) or chronic migraine (CM)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jun 2024 Fourth interim analysis results along with sub-analysis, presented in Teva Pharmaceutical Industries media release
30 Jun 2023 According to Teva Pharmaceutical Industries media release, this study is being conducted in 11 countries across Europe.
30 Jun 2023 According to Teva Pharmaceutical Industries media release, four abstracts from the third interim analysis of the PEARL study will be presented at the 9th European Academy of Neurology (EAN) Congress in Budapest, Hungary and the primary analysis is being presented as an oral presentation by Professor Cristina Tassorelli, Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy on July 1, 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com